S&P Biotech SPDR (XBI)
$83.58 0.79 (0.95%)
13:19 EDT XBI Stock Quote Delayed 15 Minutes
Previous Close $82.79
Market Cap 4.52B
PE Ratio -
Volume (Avg. Vol.) 2.41M
Day's Range 82.46 - 83.72
52-Week Range 64.38 - 97.60
Dividend & Yield 0.23 (0.27%)
XBI Stock Predictions, Articles, and S&P Biotech SPDR News
- From InvestorPlace
- From the Web
The biotech trade is always a momentum bet, and currently Wall Street is betting it will go up. I can use this play in XBI for free income.
Investors fear Amgen (AMGN) is a falling knife after dropping on earnings. Use that fear to sell puts for income in AMGN stock.
The SPDR S&P Biotech ETF is forming a bull flag. Here's how to play biotech stocks for profit in XBI.
Biotech stocks, including Celgene, are pulling back. CELG stock is one of the best dip-buying opportunities of the bunch.
ETFs should not move 11% in four days. The IBB just did that, so I will short it with no money out of pocket. Bet against the herd mentality.
XBI hit a new 52-week high of $76.60 on Tuesday before easing back slightly to about $75. And I'm opting to employ one of my preferred bullish strategies here.
Biotech stocks are quietly climbing higher. Here's how to trade the SPDR S&P Biotech (ETF) (XBI) before its seemingly imminent pop.
Like other leveraged ETFs, Direxion Daily S&P Biotech Bear 3X Shares (LABD) seduces with big potential gains when biotech stocks drop.
Biotech stocks are making a comeback. Use this bullish XBI play to capitalize on continued strength in the sector.
Biotech stocks have retraced to an attractive buy point. Consider these three plays on XBI, CELG and AMGN.
Biotech stocks and ETFs like iShares' IBB and SPDR's XBI were hammered Wednesday on Donald Trump's drug pricing comments. Opportunity knocks.
Biotech stocks have gained the wind, but the SPDR S&P Biotech (ETF) (XBI) hasn't yet caught up with the market. That's going to change soon.
The biotech stock pop is fading, but opportunity lurks for bulls and bears, and you can use the XBI ETF to make some money on its next move.
Biotech stocks remain under accumulation post-election. Play XBI on the cheap to profit from the expected continued upside.
Biotech stocks and the SPDR S&P Biotech ETF (XBI) just shook off a major bugaboo in Hillary Clinton. The XBI ETF will soar as a result.
Apple (AAPL) and the SPDR S&P Biotech ETF (XBI) are going to see selling pressure while Metlife (MET) is unlikely to see the same decline.
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!